INT109080

From wiki-pain
Revision as of 16:55, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 11
Disease Relevance 3.17
Pain Relevance 0.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (ANGPT1) signal transduction (ANGPT1) extracellular space (ANGPT1)
extracellular region (ANGPT1) plasma membrane (ANGPT1)
Anatomy Link Frequency
plasma 1
blood 1
colon 1
ANGPT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 2 98.08 Very High Very High Very High
bradykinin 6 96.40 Very High Very High Very High
Angina 1 83.76 Quite High
headache 7 76.08 Quite High
backache 6 75.28 Quite High
cytokine 25 5.00 Very Low Very Low Very Low
imagery 24 5.00 Very Low Very Low Very Low
positron emission tomography 21 5.00 Very Low Very Low Very Low
metalloproteinase 20 5.00 Very Low Very Low Very Low
Inflammatory response 18 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypertension 36 99.12 Very High Very High Very High
Cancer 480 98.04 Very High Very High Very High
Ovarian Cancer 100 93.08 High High
Pathologic Constriction 4 88.60 High High
Metastasis 90 87.24 High High
Hypersensitivity 49 86.04 High High
Cv General 3 Under Development 2 83.76 Quite High
Diarrhoea 18 76.88 Quite High
Headache 7 76.08 Quite High
Low Back Pain 6 75.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In healthy human subjects, doses of between 40 and 640 mg of aliskiren exert a dose-dependent reduction in PRA and Ang I and Ang II levels.
Negative_regulation (reduction) of Ang I
1) Confidence 0.14 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 19066408 Disease Relevance 0.39 Pain Relevance 0.20
One drug that emerged from this effort is aliskiren, a direct human renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I (Ang I).
Negative_regulation (blocks) of Ang I
2) Confidence 0.10 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 19066408 Disease Relevance 0.33 Pain Relevance 0.16
Both drugs caused a decrease in angiotensin (Ang) II level, an increase in Ang I level, and reduction in Ang II/Ang I ratio in arterial and coronary sinus blood.
Negative_regulation (reduction) of Ang I in blood
3) Confidence 0.08 Published 2003 Journal Hypertension Section Abstract Doc Link 12623947 Disease Relevance 0.08 Pain Relevance 0.34
In healthy humans, aliskiren of doses between 40 and 640 mg exerts a dose-dependent reduction in PRA, Ang I, and Ang II levels.
Negative_regulation (reduction) of Ang I
4) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.09 Pain Relevance 0
Aliskiren produced dose-dependent reductions in PRA, Ang I, and Ang II vs placebo.
Negative_regulation (reductions) of Ang I
5) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 1.00 Pain Relevance 0.13
Although both surgical methods had similar effects on Ang 1, Ang 2, and the Ang 1/Ang 2 ratio, the extent of the changes (decrease in Ang 1, increase in Ang 2, and decrease in the Ang 1/ Ang 2 ratio) was significantly greater after open colorectal resection.
Negative_regulation (decrease) of Ang 1
6) Confidence 0.05 Published 2009 Journal Surg Endosc Section Body Doc Link PMC2814196 Disease Relevance 0.09 Pain Relevance 0
A study investigating the benign pathology of open and closed colon and rectal resection patients demonstrated that both surgical methods are associated with a decrease in Ang 1 and an increase in Ang 2 levels on PODs 1 and 3 such that a significantly greater Ang 1/Ang 2 ratio was noted at both time points.
Negative_regulation (decrease) of Ang 1 in colon
7) Confidence 0.05 Published 2009 Journal Surg Endosc Section Body Doc Link PMC2814196 Disease Relevance 0.06 Pain Relevance 0
Again, aliskiren at a dose of 300 mg decreases PRA in hypertensive patients by approximately 50%–80%51,52 and reduces PRA and plasma levels of Ang I and Ang II for 48 hours.53 Furthermore, urinary aldosterone was reduced at a dose of 80 mg or more, and sodium extraction was increased to 91% at a dose of 640 mg.54 Compared with valsartan, aliskiren more strongly decreases the activity of renin in the circulation and reduces the excretion of urinary aldosterone for a longer period.53,55 Following oral administration, peak plasma concentrations of aliskiren are reached within 1–3 hours.52,53,56–58 The plasma half-life of aliskiren in humans shows a slow terminal elimination at 23–70 hours59–61 and approximately 47%–51% of aliskiren is bound by plasma proteins in humans, independent of the concentration.59,62,63 Based on in vitro studies, the major enzyme responsible for its metabolism appears to be Cytochrome P450 (CYP3A4).
Negative_regulation (reduces) of Ang I in plasma associated with hypertension
8) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.10 Pain Relevance 0
As DRI reduces PRA, the production of Ang I decreases, resulting in less substrate availability for conversion to Ang II by ACE or other enzymes.
Negative_regulation (decreases) of Ang I
9) Confidence 0.04 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0 Pain Relevance 0
Although both surgical methods had similar effects on Ang 1, Ang 2, and the Ang 1/Ang 2 ratio, the extent of the changes (decrease in Ang 1, increase in Ang 2, and decrease in the Ang 1/ Ang 2 ratio) was significantly greater after open colorectal resection.
Negative_regulation (decrease) of Ang 1
10) Confidence 0.03 Published 2009 Journal Surg Endosc Section Body Doc Link PMC2814196 Disease Relevance 0.14 Pain Relevance 0
AMG 386 is a peptibody that binds to and inhibits angiopoietin 1 and 2.
Negative_regulation (inhibits) of angiopoietin 1
11) Confidence 0.02 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 0.89 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox